Filing summary
Entity discrepancy: The supplied filing is Salarius Pharmaceuticals, Inc.’s Form 10-Q for the quarter ended September 30, 2023—not a filing for Decoy Therapeutics Inc.
Business context and reporting period
Salarius is a clinical-stage biotechnology company developing seclidemstat (SP-2577), a targeted protein inhibitor, and SP-3164, a targeted protein degrader. It has no products approved for commercial sale and reports no product-sales revenue. The financial statements cover the three and nine months ended September 30, 2023; the interim statements are unaudited.
Financial results and liquidity
| Metric | Three months ended September 30, 2023 | Three months ended September 30, 2022 | Nine months ended September 30, 2023 | Nine months ended September 30, 2022 |
|---|---|---|---|---|
| Research and development | $1.04 million | $3.79 million | $7.11 million | $11.15 million |
| General and administrative | $1.50 million | $1.83 million | $4.81 million | $5.35 million |
| Total operating expenses | $2.53 million | $14.49 million | $11.92 million | $25.36 million |
| Net loss | $2.44 million | $14.41 million | $11.66 million | $25.24 million |
| Net loss per share, basic and diluted | $0.65 | $6.41 | $3.84 | $12.13 |
Cash and cash equivalents were $7.58 million at September 30, 2023, down from $12.11 million at December 31, 2022. Nine-month operating cash use was $11.33 million, compared with $12.88 million in the prior-year period; financing provided $6.81 million, primarily from equity offerings. Working capital was $6.0 million. Current liabilities included $459,091 of notes payable; the filing says the short-term insurance-financing note carried a 7.87% interest rate.
The company reported an accumulated deficit of $75.47 million and total stockholders’ equity of $6.08 million. Gross or operating margins are not meaningfully reported because the company has no product-sales revenue. It received its final CPRIT grant reimbursement in the first quarter of 2023; the grant was closed by September 30, 2023, with no remaining grant receivable.
Material changes versus the prior comparable period
- Third-quarter R&D expense fell by $2.75 million year over year, which management attributed primarily to the cost-savings plan. Nine-month R&D fell by $4.04 million, reflecting lower SP-2577 spending and reduced activity, partly offset by higher SP-3164 spending.
- Third-quarter net loss was substantially lower than the prior-year quarter, which included an $8.87 million goodwill impairment. There was no goodwill impairment in 2023.
- Nine-month financing cash inflow increased to $6.81 million from $1.99 million, including proceeds from an ATM offering and a May 2023 private placement. Common shares outstanding rose to 3,938,433 at September 30, 2023 from 2,255,899 at year-end 2022.
- The company recorded approximately $0.3 million of workforce-separation costs in the third quarter, of which $0.1 million remained accrued at quarter-end.
Outlook, risks, and contingencies
- Going concern and funding: Management said cash was expected to fund reduced operations through the first quarter of 2024, but the company needs additional capital within the next several months. The filing states that substantial doubt exists about its ability to continue as a going concern; financing or strategic-partner plans are not assured. Failure to secure funding or a transaction could lead to cessation of operations, liquidation, or bankruptcy protection.
- Strategic review and restructuring: Since August 2023, Canaccord Genuity has advised on a review of alternatives, potentially including a merger, acquisition, asset sale, licensing, or other transaction. There is no set timetable or assurance of a transaction. The workforce was reduced by more than 50%; management expects R&D spending to decline through the remainder of 2023 and into 2024.
- Clinical and regulatory: The FDA cleared the SP-3164 IND in July 2023 for a trial in relapsed/refractory non-Hodgkin lymphoma. After an October 13, 2023 end-of-Phase 2 meeting concerning SP-2577 for Ewing sarcoma, the company said it was preparing a trial-protocol amendment for submission in the fourth quarter of 2023. These are forward-looking plans, not completed outcomes.
- Nasdaq listing: The company received notice that its share price was below Nasdaq’s $1.00 minimum bid requirement. It had until March 4, 2024 to regain compliance under the initial 180-day period; delisting remained a risk.
- Potential dilution and transaction terms: As of September 30, 2023, approximately 10.84 million warrants were outstanding, including 2.72 million pre-funded warrants. Warrant terms may dilute existing holders, affect financing, and require a successor to assume obligations in certain fundamental transactions.
- The company disclosed no material legal proceedings. It also warned that strategic-review costs, restructuring costs, and obligations or contingent liabilities could reduce cash available, including in a potential liquidation.
Important facts for investors to verify
- Confirm the issuer: this filing is for Salarius Pharmaceuticals, Inc., not Decoy Therapeutics Inc.
- Check subsequent filings for cash runway, new financing or partnership activity, strategic-review developments, and any decision to wind down operations.
- Verify Nasdaq bid-price compliance and any change in listing status.
- Track SP-2577 protocol-amendment submission and FDA-related next steps, as well as the status and funding of SP-3164 development.
- Review the fully diluted share count, warrant exercises and terms, and potential dilution or transaction-related warrant obligations.